Thanks for that important question.
I think we've all heard medical experts talking about this as another really important tool, and it is an important tool. These treatments are important to have in Canada, particularly for high-risk groups and the immunocompromised. The therapeutics are targeted for different groups, but for that group in particular.
In anticipation of the approval of Pfizer's antiviral treatment Paxlovid, we secured one million courses of the treatment in December. We also secured 500,000 treatment courses of Merck's antiviral pill. We announced the shipment of more than 30,000 Paxlovid treatments the day it received regulatory approval, and that was just working in advance, hoping the approval was going to come in, working with the suppliers and trying to ensure that the time lag was minimal. In fact, on this, it was the same day. We have another 120,000 on their way for the end of this quarter.
I would say that as of March this year, we've secured more than 1.7 million treatment courses from nine different therapeutics.